Please assess the completion status of the following clinical trial:

Trial Title: Assessing Tele-Health Outcomes in Multiyear Extensions of PD Trials

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Enrollment in STEADY-PD3 or SURE-PD3 studies~2. Prior consent to be contacted by the University of Rochester (UR) or if a participant from STEADY-PD III or SURE-PD3 studies directly contacts UR to request information about study participation~3. Internet-enabled device that will support participation in tele-visits~4. Have created or willing to create a Global Unique Identifier (GUID)~5. Willing and able to provide informed consent~6. English fluency~7. For participants opting to participate in the smartphone component, possession of a suitable smartphone (iPhone or Android) with adequate data plan and cellular network access/signal or wifi access~Exclusion Criteria:~1. Inability to carry out study activities as determined by study staff

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- former phase 3 PD trial participants (Type: None): The AT-HOME PD cohort enrolled upon completion of STEADY-PD3 or during completion of SURE-PD3; enrolling 2 to 6 years after diagnosis, and on standard dopaminergic therapy for 0 to 3 years. Former STEADY-PD3 participants had been randomized (1:1) to 3 years of isradipine or placebo treatment; SURE-PD3 participants had been randomized (1:1) to 2 years of inosine or placebo treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).